ReviewExperimental and therapeutic medicine2026
Benefits and mechanisms of polysaccharides derived from traditional Chinese medicine for ulcerative colitis treatment (Review).
Review in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by abdominal pain, diarrhea and bloody mucopurulent stools. The UC global incidence is rising and conventional therapies remain limited. Therefore, there is an urgent need for novel treatments. Polysaccharides derived from traditional Chinese medicine (TCM) have emerged as promising candidates due to their multifaceted bioactivities. Preclinical studies have demonstrated that these polysaccharides can regulate immune system pathways, thereby reducing intestinal inflammation and oxidative stress. This protects the intestinal mucosal barrier, enhances tight junction protein expression and modulates the gut microbiota. However, their precise molecular targets and structure-activity associations remain to be fully elucidated. Translational advancement is currently constrained by challenges such as undefined mechanisms, poor oral bioavailability and a lack of clinical validation. Therefore, the present review focused on a number of polysaccharides derived from TCM herbs. The aim of the present review was to systematically analyze their functions and mechanisms for UC prevention and treatment, thus underscoring the necessity for integration of mechanistic discovery with innovative delivery strategies to facilitate the clinical translation of TCM polysaccharides in UC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.